Ophthalmology Times’ Post

Genentech, a member of the Roche group, has received FDA approval to relaunch Susvimo (ranibizumab injection 100 mg/mL) for intravitreal use via an ocular implant for treating people with wet (or neovascular) age-related macular degeneration (AMD). Susvimo is a refillable implant approximately the size of a grain of rice, and it sits within the eye, just under the upper eyelid. It continuously releases a specialized formulation of ranibizumab. Susvimo provides continuous delivery of a customized formulation of ranibizumab via the Port Delivery Platform, while other currently approved treatments may require multiple eye injections per year. In October 2022, the company launched a voluntary recall of the implant after it detected an issue with the device. The issue was uncovered when the company tested its commercial supply by puncturing the implants multiple times. Read More: https://ow.ly/QPbf50SxSMG

Bausch + Lomb has shared the results of its inaugural State of Dry Eye survey which showed that many Americans experience dry eye symptoms, but most don’t understand the severity or treatment options available. According to the company, majority of respondents to the survey did not know that their symptoms (redness, fluctuating vision, a scratchy, gritty, tired or heavy feeling, or overall eye irritation etc.) were even associated with eye dryness. Read More: https://ow.ly/O51s50Sx8qF

The CHAMP phase 3 study showed that NVK002 atropine 0.01% (Vyluma Inc.) “meaningfully slowed” myopia progression in myopic pediatric patients over a 36-month period, according to Rupa K. Wong, MD, who presented the study findings at the annual meeting of the American Association for Pediatric Ophthalmology and Strabismus. Myopia has become a global public health threat and extensive efforts are underway worldwide to identify treatments to control progression. The use of atropine in various concentrations has been evaluated in a number of studies. Read more: https://ow.ly/WacM50Sx8w5

Digitally guided systems, which relieve surgeons from using goniolenses, facilitate more accurate and faster performance of minimally invasive glaucoma surgery (MIGS) procedures by more surgeons. These benefits, in turn, translate to more consistent and better outcomes for both surgeons and patients, according to lead author Michael Berlin. Berlin is the founder and director of the Glaucoma Institute of Beverly Hills Research Foundation and a clinical professor at the University of California, Los Angeles Stein Eye Institute. Read More: https://ow.ly/RmJ850SwTIU

Andrew Lee, MD, and Andrew Carey, MD, sit down on another episode of the NeuroOp Guru to discuss a unique case of a 15-year-old who showed signs of meningioma with epithelial whirls and some psammoma bodies in the eye. Watch: https://ow.ly/hZmZ50SwTxv

Genentech announced the FDA has approved faricimab-svoa (Vabysmo) 6.0 mg single-dose prefilled syringe (PFS) for use in the treatment of wet, or neovascular, age-related macular degeneration (AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO). The single-dose prefilled syringe offers the same medication as existing Vabysmo vials, and offers physicians an alternative, ready-to-use option. It will continue to be available in a 6.0 mg vial. Read More: https://ow.ly/Z9Jf50SwTvC

Test evaluates, quantifies ocular dominance for robust monovision correction. The SimVis Gekko eye dominance strength test may change the standard of care. Read More: https://ow.ly/j5SY50StOXl

Alcon has announced the closing of its deal to acquire BELKIN Vision which includes a total upfront consideration of $81 million, including a cash payment of approximately $65 million. Read More: https://ow.ly/4FWH50StOc4

In the Ophthalmology Times Case of the Quarter series, Katherine Talcott, MD, shared 2 cases of geographic atrophy (GA) and highlighted the importance of multimodal imaging to diagnose and monitor GA progression. Read More: https://lnkd.in/efcWQry2

The US Food and Drug Administration (FDA) has approved biosimilar to Eylea, aflibercept-mrbb (Ahzantive), for the treatment of patients with age-related neovascular (wet) macular degeneration (nAMD). The biosimilar has also been approved for treatment in patients with serious retinal diseases such as diabetic macular edema (DME), diabetic retinopathy (DR) and macular edema following retinal vein occlusion (RVO). Read More: https://lnkd.in/ezv6gnVE